Overlooked molecular machine in cell nucleus may hold key to treating aggressive leukemia
(Cincinnati Children's Hospital Medical Center) Many people fighting a very aggressive form of acute myeloid leukemia (AML) don't survive more than five years. These very sick patients are often unable to receive the only cure -- a bone marrow transplant. Now, an international team of scientists report in Nature Cell Biology on a long-overlooked part of a leukemic cell's internal machinery, where they may have found a key to treating the aggressive blood cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 22, 2019 Category: Cancer & Oncology Source Type: news

A Gene Therapy Breakthrough Could Offer a Treatment for the Rare and Deadly ‘Bubble Boy’ Disease
Researchers used an experimental gene therapy to develop a possible treatment for a rare and deadly immune disorder known as “bubble boy” disease, the National Institutes of Health (NIH) announced Wednesday. Because of a gene mutation, babies who are born with X-linked severe combined immunodeficiency (X-SCID) do not develop immune cells properly, leaving them highly susceptible to infections. The condition, which strikes up to one in 50,000 newborns, primarily affects boys and requires extreme measures to prevent infection. In one famous case, a boy with SCID, David Vetter, lived in a sterile plastic “bu...
Source: TIME: Health - April 18, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Research Source Type: news

Living With Cancer: The Lifesaving Power in Stem Cells
Liars and thieves should not be allowed to detract from legitimate scientific research that has made umbilical cord blood mystic in its regenerative powers. (Source: NYT Health)
Source: NYT Health - April 18, 2019 Category: Consumer Health News Authors: SUSAN GUBAR Tags: Stem Cells Blood Donation Bone Marrow Transplants Leukemia Pregnancy and Childbirth Health Insurance and Managed Care Cancer Parenting Broxmeyer, Hal E Indiana University Source Type: news

The Leukemia Atlas: researchers unveil proteins that signal disease
(University of Texas at San Antonio) Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis. To improve that survival rate, researchers at The University of Texas at San Antonio (UTSA) and the University of Texas MD Anderson Cancer Center created an online atlas to identify and classify protein signatures present at AML diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 17, 2019 Category: Cancer & Oncology Source Type: news

Key protein a possible new target in the treatment of pancreatic cancer
(Stand Up To Cancer) Pancreatic Cancer Collective-funded research (Lustgarten Foundation and Stand Up To Cancer) from Dr. Tony Hunter (Salk Institute) and the SU2C-CRUK-Lustgarten Pancreatic Cancer Dream Team has found the presence of a key protein (Leukemia Inhibitory Factor or LIF) in PDAC microenvironment may be an exploitable treatment target to slow tumor progression or metastasis and may lead to the development of new targeted strategies for pancreatic cancer therapy. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 17, 2019 Category: International Medicine & Public Health Source Type: news

Reasons for TKI Discontinuation ID'd in Chronic Myeloid Leukemia
TUESDAY, April 16, 2019 -- For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online March 16... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 16, 2019 Category: Pharmaceuticals Source Type: news

Probing the mystery of drug resistance: New hope for leukemia's toughest cases
(Boston Children's Hospital) Alejandro Gutierrez, MD, a researcher at the Dana-Farber/Boston Children's Cancer and Blood Disorders Center has made it his mission to figure out why leukemia treatments cure some patients but not others. He and 15 colleagues report progress on two important fronts: They shed light on how leukemia cells become resistant to drugs, and they describe how two drugs used in combination may overcome that resistance, offering new hope to thousands of children and adults with leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 16, 2019 Category: Cancer & Oncology Source Type: news

Scanning for cancer treatment
(Harvard University) 11,000 people are predicted to die from acute myeloid leukemia (AML) in 2019. Recently, drug developers designed a new treatment to target the cancer's mutated genes. But, these drugs don't always work. Now, in a new study, researchers investigate both sides of the drug-body relationship to better understand why certain AML treatments--and other cancer treatments--may not work as expected. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2019 Category: Cancer & Oncology Source Type: news

Presence of Leukemia Cutis Tied to Worse Survival in AML
Hazard ratios for leukemia - specific death, all - cause death higher for patients with AML and LC (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 11, 2019 Category: Cancer & Oncology Tags: Dermatology, Oncology, Journal, Source Type: news

CAR T-Cell Therapy for Mesothelioma Proving Effective in Clinical Trial
Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center believes novel CAR T-cell therapy will be part of future, standard-of-care treatment for malignant pleural mesothelioma. The therapy involves the laboratory reprograming of a patient’s T cells — a type of white blood cell — to attack the cancer by targeting mesothelin, a surface protein. CAR T-cell therapy is a form of immunotherapy that could extend mesothelioma survival significantly. “That’s my goal. That’s what we’ve been working toward for many years,” Adusumilli told The Mesothelioma Center at Asbestos.com....
Source: Asbestos and Mesothelioma News - April 11, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Presence of Leukemia Cutis Tied to Worse Survival in AML
THURSDAY, April 11, 2019 -- For patients with acute myeloid leukemia (AML), the presence of leukemia cutis (LC) is associated with decreased overall and leukemia-specific survival, according to a study published online April 10 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2019 Category: Pharmaceuticals Source Type: news

Venetoclax Plus LDAC May Benefit Patients with AML Ineligible for Intensive Chemotherapy
A new study evaluated combination venetoclax and low-dose cytarabine in previously untreated acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - April 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Phase III SIERRA Trial Finds Iomab-B Promising for Relapsed/Refractory AML
Researchers are evaluating  Iodine (131I) apamistamab plus HCT vs conventional care in older patients with active relapsed/refractory acute myeloid leukemia. (Source: CancerNetwork)
Source: CancerNetwork - April 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Mutation stands in the way of healthy blood cell maturation
(University of Copenhagen The Faculty of Health and Medical Sciences) In a new study, researchers from the University of Copenhagen and EMBL in Heidelberg have learned how a specific genetic mutation affects the maturation of blood cells in mouse models. Leukemia patients often have a mutation in this gene, often seen before the disease sets in. The researchers are working on a strategy for treating the mutation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 5, 2019 Category: International Medicine & Public Health Source Type: news

Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
TOKYO and BASKING RIDGE, N.J., April 4, 2019 -- (Healthcare Sales & Marketing Network) -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the N... Biopharmaceuticals, Oncology, FDA Daiichi Sankyo, quizartinib, acute myeloid leukemia, FLT3 inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 4, 2019 Category: Pharmaceuticals Source Type: news

Doctors: When Opposites Attract, for Life
Of all the obstacles to initiating hospice care that have been cited, the devotion of wife to husband, or child to parent, is the hardest to quantify. (Source: NYT Health)
Source: NYT Health - April 4, 2019 Category: Consumer Health News Authors: MIKKAEL A. SEKERES, M.D. Tags: Elder Care Leukemia Spleen Doctors Hospice Care Hospitals Source Type: news

A step toward recovering reproduction in girls who survive childhood cancer
(University of Michigan) Leukemia treatments often leave girls infertile, but a procedure developed by researchers at the University of Michigan working with mice is a step toward restoring their ability to be biological mothers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2019 Category: International Medicine & Public Health Source Type: news

Genome Sequencing Shows Clinical Promise in AML and ALL Genome Sequencing Shows Clinical Promise in AML and ALL
Whole genome sequencing could soon be used clinically to better characterise tumour profiles in leukaemia patients, potentially improving genomic stratification and therapy choices, say UK scientists.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 2, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

In the Loop: Gabe's bell to 'honor the fighting, remember the resting, and party on with the survivors'
Gabe Carranza walked into the lobby on the 16th floor of the Mayo Building. It was a walk he'd made more times than he could count over the past three years and 70 days. But this walk was different. It marked the end of Gabe's treatment for?acute lymphoblastic leukemia. The lobby was filled with family, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 2, 2019 Category: Databases & Libraries Source Type: news

AACR: Longer Survival With Gilteritinib in FLT3mut & #43; AML
MONDAY, April 1, 2019 -- For patients with FMS-like tyrosine kinase 3 (FLT3) mutations who have relapsed or refractory acute myeloid leukemia (AML), gilteritinib results in longer overall survival and higher response rates than salvage chemotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 1, 2019 Category: Pharmaceuticals Source Type: news

Leukemia pill cuts death risks by 36% for 21,000 people with a hard-to-treat form of the cancer
Gilteritinib was approved by the US Food and Drug Administration in November 2018. its latest trial, conducted at the University of Pennsylvania found it improves both survival and quality of life. (Source: the Mail online | Health)
Source: the Mail online | Health - April 1, 2019 Category: Consumer Health News Source Type: news

New drug represents 'paradigm shift' in treatment of acute myeloid leukemia
A paradigm shift is underway in the treatment of acute myeloid leukemia: The newest of personalized medicines proved more effective and less toxic than standard chemotherapy for certain acute myeloid leukemia patients, new research indicates. (Source: CNN.com - Health)
Source: CNN.com - Health - April 1, 2019 Category: Consumer Health News Source Type: news

Practice-Changing Results Seen in Phase III Relapsed/Refractory AML Trial
Results of the phase III ADMIRAL trial, which tested the FLT3 inhibitor gilteritinib in patients with relapsed/refractory acute myeloid leukemia, were presented at the AACR Annual Meeting. (Source: CancerNetwork)
Source: CancerNetwork - April 1, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Gilteritinib improved survival for patients with acute myeloid leukemia
(American Association for Cancer Research) Treatment with the FLT3-targeted therapeutic gilteritinib (Xospata) improved survival for patients with relapsed or refractory acute myeloid leukemia (AML) harboring a FLT3 mutation compared with standard chemotherapy regimens, according to results from the ADMIRAL phase III clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Targeted drug for leukemia tested at Penn Medicine helps patients live longer
(University of Pennsylvania School of Medicine) An inhibitor drug that targets a specific mutation in relapsed or refractory acute myeloid leukemia (AML) helps patients live almost twice as long as those who receive chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

Five-year-old who won the nation’s heart in his battle against leukaemia has found a stem-cell donor
Oscar Saxelby-Lee, of St John's, Worcester, was diagnosed with the aggressive blood cancer acute lymphoblastic leukaemia on December 28 last year after his parents noticed bruising. (Source: the Mail online | Health)
Source: the Mail online | Health - March 29, 2019 Category: Consumer Health News Source Type: news

Genomic analysis offers roadmap for diagnosis and treatment of a high-risk leukemia
(St. Jude Children's Research Hospital) Acute erythroid leukemia (AEL) is a high-risk cancer with a dismal prognosis, uncertain genetic basis and controversy surrounding the diagnosis. That is changing, thanks to research led by St. Jude Children's Research Hospital that appears today in the journal Nature Genetics.The researchers completed the largest, most comprehensive genomic analysis yet of AEL and identified six age-related subgroups with distinct mutations and patterns of gene expression as well as treatment outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 29, 2019 Category: Cancer & Oncology Source Type: news

Heating up tumors could make CAR T therapy more effective, study finds
UCLAZhen GuFINDINGSA preclinical study led by scientists at theUCLA Jonsson Comprehensive Cancer Center suggests that heating solid tumors during CAR T-cell therapy can enhance the treatment ’s success.The researchers found that when a heating technique called photothermal ablation was combined with the infusion of CAR T cells, it suppressed melanoma tumor growth for up to 20 days in mice. Among the mice that were treated with the combination, 33 percent were still tumor free after the 20-day mark.BACKGROUNDT cells that have been genetically engineered with chimeric antigen receptor, or CAR, have successfully been us...
Source: UCLA Newsroom: Health Sciences - March 27, 2019 Category: Universities & Medical Training Source Type: news

Moffitt CEO to be inducted into the 2019 Florida Inventors Hall of Fame
President and CEO of  Moffitt Cancer Center, Dr. Alan List, is being inducted into the 2019 Florida Inventors Hall of Fame for developing new therapeutic strategies for treating blood cancers. Internationally recognized for his contributions in the development of more effective treatment strategies for myelodysplasti c syndrome and acute myeloid leukemia, List's work led to the development of lenalidomide, which received approval from the U.S. Food and Drug Administration. The treatment transformed… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 27, 2019 Category: Pharmaceuticals Authors: Kelsey Sunderland Source Type: news

FDA Scrambles to Prevent Shortages Amid Sterilization Shutdowns
Shutdowns of two facilities that use ethylene oxide to sterilize medical devices have raised concern about potential shortages in the medtech industry because this is such a popular sterilization method for medical devices. Ethylene oxide (EtO) is a flammable, colorless gas used to make a range of products. EtO also is used to sterilize equipment and plastic devices that cannot be sterilized by steam, such as medical equipment. In fact, about half of all sterilized medical devices undergo sterilization using this gas. According to the EPA, long-term exposure to EtO can irritate the eyes,...
Source: MDDI - March 26, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Sterilization Regulatory and Compliance Source Type: news

HSCT Remains Standard in Childhood ALL, Despite CAR T-Cells HSCT Remains Standard in Childhood ALL, Despite CAR T-Cells
Clinicians should continue to rely on matched donor stem cell transplants to treat childhood acute lymphoblastic leukemia, while more data on novel CAR T-cell therapies is gathered, says German expert.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 26, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

A compound found in goldenseal proven to possess cancer-fighting properties
(Natural News) Scientists continue to search for natural cancer treatments. A team of researchers at Nagasaki International University in Japan found that a natural compound known as berberine can help protect against cancer, particularly leukemia, by inducing cancer cell death. For the study, the research team looked at the subcellular localization and the apoptotic mechanisms... (Source: NaturalNews.com)
Source: NaturalNews.com - March 26, 2019 Category: Consumer Health News Source Type: news

Thriving college student, 18, who passed off cough as freshman flu is diagnosed with leukemia
Marlee Pincus, 18, began coughing in September 2018, but thought she had come down with the flu. She was eventually taken to the hospital where she was diagnosed with leukemia, a blood cancer. (Source: the Mail online | Health)
Source: the Mail online | Health - March 25, 2019 Category: Consumer Health News Source Type: news

How 'sleeper cell' cancer stem cells are maintained in chronic myelogenous leukemia
(University of Alabama at Birmingham) Even when chronic myelogenous leukemia is in remission, 'sleeper cell,' quiescent leukemic stem cells are maintained in microenvironments in the bone marrow. This maintenance is poorly understood. Researchers now describe how niche-specific expression of a particular chemokine by a particular type of bone marrow cell controls quiescence of these treatment-resistant leukemic stem cells. The chemokine is CXCL12, and the particular bone marrow cells expressing it are mesenchymal stromal cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news

Study gives new perspective on production of blood cells and immune cells
(University of California - Santa Cruz) A new study provides a thorough accounting of blood cell production from hematopoietic stem cells. The results are important for understanding disorders such as anemia, diseases of the immune system, and blood cancers such as leukemias and lymphomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 21, 2019 Category: Cancer & Oncology Source Type: news

Research paves way for new source for leukemia drug
(Oregon State University) Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2019 Category: International Medicine & Public Health Source Type: news

New treatment of acute myeloid leukemia achieves remarkable results in a disease formerly with little hope
(Monash University) A new Australian drug trial has achieved a remarkable result, clearing the bone marrow of leukemia in almost 60 percent of patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 20, 2019 Category: International Medicine & Public Health Source Type: news

Favorable Outcomes Seen in Long Term for ALLR3 Trial
Findings for risk - stratified tx in B - cell precursor acute lymphoblastic leukemia, late bone marrow relapse (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 19, 2019 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Journal, Source Type: news

Favorable Outcomes Seen in Long Term for ALLR3 Trial
TUESDAY, March 19, 2019 -- For children with B-cell precursor acute lymphoblastic leukemia with late bone marrow relapse, risk stratification by minimal residual disease seems to be an effective strategy for treatment, according to a study recently... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 19, 2019 Category: Pharmaceuticals Source Type: news

Epigenetic protein could be new therapeutic target in acute myeloid leukemia
(Rockefeller University Press) British researchers have discovered that an epigenetic protein called EZH2 delays the development of acute myeloid leukemia (AML) but then switches sides once the disease is established to help maintain tumor growth. The study, which will be published March 19 in the Journal of Experimental Medicine, suggests that targeting EZH2 could therefore be an effective treatment for AML, an aggressive blood cancer expected to kill over 10,000 people in the US alone this year. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 19, 2019 Category: Cancer & Oncology Source Type: news

Oscar Saxelby-Lee: Mum 'overwhelmed' by stem cell donor campaign
Thousands of people have registered to find a stem cell match for a five-year-old with leukaemia. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - March 14, 2019 Category: Consumer Health News Source Type: news

Hematopoietic stem cells: Making blood thicker than water
(Osaka University) An Osaka University-led team revealed that Ragnase-1 is a key regulator of the self-renewal and differentiation of hematopoietic stem and progenitor cells. Knockout of this gene in mice resulted in aberrant blood cell composition and hematopoiesis, and caused health-related outcomes such as low hemoglobin, enlarged spleen, and early death. This insight into blood cell homeostasis and differentiation could lead to treatments for diseases such as leukemia in which these regulatory processes go awry. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 13, 2019 Category: International Medicine & Public Health Source Type: news

Genetically encoded sensor isolates hidden leukemic stem cells
(American Friends of Tel Aviv University) Tel Aviv University researchers have devised a novel biosensor that can isolate and target leukemic stem cells. It can provide a prototype for precision oncology efforts to target patient-specific cells to fight the deadly disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2019 Category: Cancer & Oncology Source Type: news

Starving leukemia cells by targeting amino acids
(Emory Health Sciences) Eliminating ASCT2 selectively stops the growth of leukemia cells, while having limited effects on healthy blood cells and hematopoetic (blood-forming) stem cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2019 Category: Cancer & Oncology Source Type: news

Blood donation: 'For two weeks she lived life to the full'
Marilyn's daughter Alice needed 144 blood transfusions for leukaemia treatment. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - March 11, 2019 Category: Consumer Health News Source Type: news

Only About Half of Elderly Newly Diagnosed With ALL Receive Tx
FRIDAY, March 8, 2019 -- Almost half of elderly patients newly diagnosed with acute lymphoblastic leukemia (ALL) do not receive treatment, according to a study recently published in Leukemia& Lymphoma. Christopher Kim, M.P.H., Ph.D., from Amgen... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 8, 2019 Category: Pharmaceuticals Source Type: news

Potential Link Between Industrial Pollutants and Acute Myeloid Leukemia Examined
A recent study evaluated whether living in an industrial city could be an important risk factor for developing AML. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Leukemia caused by collision with a wild pig? - Zimmermann M, Bendas G, Feldmann G.
HISTORY:  A 23 years old, previously healthy woman was admitted to our clinic with neutropenic fever to rule out acute leukemia. Upon admission the patient reported that a few days ago the carcass of a pig had fallen on her from above, so that she experi... (Source: SafetyLit)
Source: SafetyLit - March 7, 2019 Category: International Medicine & Public Health Tags: Non-Human Animals and Insects Source Type: news

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Investor Update)
Source: Roche Investor Update - March 7, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Media News)
Source: Roche Media News - March 7, 2019 Category: Pharmaceuticals Source Type: news